Nucala denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for nucala are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Nucala as "Experimental" — and Why This Is Likely Wrong

Nucala (mepolizumab) is an FDA-approved biologic with established regulatory approval for severe eosinophilic asthma and several other indications. An "experimental or investigational" denial for an FDA-approved medication typically signals one of three things: the specific indication being treated falls outside the approved label and Cigna's policy does not recognize it as covered; the supporting documentation submitted did not establish the approved indication clearly enough; or a policy was applied in error. In all three scenarios, the denial is appealable.

If the use is on-label, Cigna's experimental denial is almost certainly incorrect and the appeal should lead with FDA approval status as the threshold argument.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): You are entitled to a full-and-fair review. Submit within the deadline on your denial notice.
• External review: Available after internal remedies are exhausted, typically within approximately four months of a final adverse determination. An IRO reviewer will independently assess whether Nucala meets the standard of care for the documented indication.
• Expedited review: Available when asthma control is severely compromised and standard timelines would cause harm.

## Concrete Appeal Steps

1. Obtain the FDA-approved prescribing label for Nucala and confirm which indication applies to your patient. 2. Pull Cigna's published coverage policy for Nucala and identify the specific language that triggered the experimental denial. 3. Have the prescribing allergist, pulmonologist, or specialist write a letter addressing the exact language in Cigna's policy. 4. Submit the appeal with the prescribing label and clinical letter as the primary exhibits.

## Documentation to Gather

• Diagnosis confirmation: Confirmed indication (e.g., severe eosinophilic asthma) with supporting chart documentation and eosinophil count.
• FDA labeling: Copy of the approved prescribing information confirming the indication.
• Prior treatment history: Inadequate response to standard controller therapy, documented with dates and outcomes.
• Clinical severity: Exacerbation frequency, hospitalizations, oral corticosteroid use, pulmonary function documentation.
• Prescriber medical-necessity letter: Directly refutes the experimental characterization by citing FDA approval and the applicable specialist society guideline (generically referenced).

## Criteria-Mapping Structure

Pull Cigna's coverage policy and the FDA-approved label. In a side-by-side format, list each criterion Cigna cites and the chart and label evidence that satisfies it. Lead with the FDA approval status prominently — this is the foundational rebuttal to an experimental denial. Reference the applicable asthma or eosinophilic disease guideline organization generically (e.g., the applicable GINA or immunology society guideline) to underscore that Nucala represents the established standard of care for the documented indication.